← back to search

Kyu‐pyo Kim

Ulsan College · KR
Area of research
Oncology · Surgery
Research interest
Research interests include Pancreatic and Hepatic Oncology Research, Cholangiocarcinoma and Gallbladder Cancer Studies, Colorectal Cancer Treatments and Studies, and Hepatocellular Carcinoma Treatment and Prognosis.
h-index
40
citations
5,773
works
300
NIH funding
primary concept
Medicine
email

Recent publications

Bevacizumab plus Erlotinib in Advanced Solid Cancers with Krebs Cycle Gene Mutations: A Multicenter Phase II Study (BRISK; KCSG AL22-16).
2026cited by 0position: contributordoi
Liposomal irinotecan for previously treated patients with biliary tract cancer: A pooled analysis of NIFTY and NALIRICC trials
Journal of Hepatology 2025cited by 13position: middledoi
Multicenter Phase 2 Trial of Second-Line Regorafenib in Patients with Unresectable Hepatocellular Carcinoma after Progression on Atezolizumab plus Bevacizumab
Liver Cancer 2025cited by 12position: middledoi
Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as a Potential Biomarker for Immune Checkpoint Inhibitors in Patients with Biliary Tract Cancer
Clinical Cancer Research 2024cited by 19position: middledoi
Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as a Potential Biomarker for Immune Checkpoint Inhibitors in Patients with Biliary Tract Cancer.
2024cited by 13position: contributordoi
Comparison of surgical outcomes for hip fracture between older patients with and without cancer: a propensity score matching analysis.
2024cited by 3position: contributordoi
Prognostic value of tumor-infiltrating lymphocytes in distal extrahepatic bile duct carcinoma.
2024cited by 1position: contributordoi
Supplementary Data1 from Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as a Potential Biomarker for Immune Checkpoint Inhibitors in Patients with Biliary Tract Cancer
2024cited by 0position: contributordoi
Data from Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as a Potential Biomarker for Immune Checkpoint Inhibitors in Patients with Biliary Tract Cancer
2024cited by 0position: contributordoi
Treatment With Liposomal Irinotecan Plus Fluorouracil and Leucovorin for Patients With Previously Treated Metastatic Biliary Tract Cancer
JAMA Oncology 2023cited by 81position: middledoi
Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform
The Oncologist 2023cited by 54position: middledoi
Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial
Hepatology 2023cited by 52position: contributordoi
Multifunctional microrobot with real-time visualization and magnetic resonance imaging for chemoembolization therapy of liver cancer
Science Advances 2022cited by 131position: middledoi
Multifunctional microrobot with real-time visualization and magnetic resonance imaging for chemoembolization therapy of liver cancer.
2022cited by 67position: contributordoi
A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies.
2022cited by 7position: contributordoi
Correction to: A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies.
2022cited by 0position: contributordoi
Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study
The Lancet Oncology 2021cited by 216position: middledoi
Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations.
Journal of Clinical Oncology 2019cited by 78position: middledoi
Neoadjuvant FOLFIRINOX in patients with (borderline) resectable pancreatic cancer: A systematic review and patient-level meta-analysis.
Journal of Clinical Oncology 2018cited by 51position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Changhoon Yoo · Eastern Hepatobiliary Surgery Hospital6 papers (2021–2025) · 6 papers (2022–2024)Baek‐Yeol Ryoo · Ulsan College4 papers (2021–2025)Jae Ho Jeong · Ulsan College3 papers (2021–2024)Jaekyung Cheon · Ulsan College3 papers (2021–2025)Ji Sung Lee · Gujarat Institute of Desert Ecology3 papers (2021–2025)Hyewon Ryu · Chungnam National University3 papers (2021–2025)Jill Lacy · Yale Cancer Center2 papers (2018–2023)Do‐Youn Oh · New Generation University College2 papers (2019–2023)Jaewon Hyung · Case Western Reserve University2 papers (2023–2025)Hong Jae Chon · Portsmouth Hospitals NHS Trust2 papers (2023–2025)Andrew H. Ko · UCSF Helen Diller Family Comprehensive Cancer Center2 papers (2018–2023)Richard S. Finn · United States Olympic & Paralympic Committee2 papers (2024–2025) · 2 papers (2024–2025)Ghassan K. Abou‐Alfa · Verizon (United States)2 papers (2021–2023)Myoung Joo Kang · Inje University Haeundae Paik Hospital2 papers (2021–2023)Kyung Won Kim · Ulsan College2 papers (2021–2023)Byung Woog Kang · Kyungpook National University Hospital2 papers (2021–2023)Iwona Dobler · Takeda Pharmaceuticals USA Inc2 papers (2022–2022)Toshio Shimizu · Wisdom Health (United States)2 papers (2022–2022)